• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一名年轻女性肾盂微乳头尿路上皮癌表现为原发灶不明的恶性肿瘤,尿细胞学涂片细胞角蛋白20/p53表达双重免疫染色的诊断效用

Diagnostic utility of double immunostaining of a urine cytology preparation for cytokeratin 20/p53 expression in a young woman with micropapillary urothelial carcinoma of the renal pelvis presenting as an unknown primary malignancy.

作者信息

Kim Hyun-Jung, Sung Lucky, Kim Jung-Yeon, Park Kyeongmee

机构信息

Address: Department of Pathology, Inje University, Sanggye Paik Hospital, Seoul, Korea.

Department of Urology, Inje University, Sanggye Paik Hospital, Seoul, Korea.

出版信息

Cytojournal. 2016 Nov 16;13:26. doi: 10.4103/1742-6413.194162. eCollection 2016.

DOI:10.4103/1742-6413.194162
PMID:27994635
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5137237/
Abstract

Atypical urine cytology (CYT) triggers a cystoscopic or another ancillary investigation that targets urothelial neoplasms. We report a case presenting as an unknown primary malignancy, which illustrated the diagnostic utility of direct double immunostaining for cytokeratin 20 (CK20)/p53 expression in a urine CYT specimen. A 42-year-old woman visited the emergency room for pain in her right lower abdominal quadrant. Computed tomography revealed postrenal obstructive hydronephrosis, and her urine CYT showed malignancy, type undetermined. Atypical cells that are positive for cytoplasmic expression of CK20 and nuclear expression of p53 could facilitate the decision to perform a nephroureterectomy for urothelial carcinoma.

摘要

非典型尿细胞学检查(CYT)会引发针对尿路上皮肿瘤的膀胱镜检查或其他辅助检查。我们报告了一例表现为原发灶不明恶性肿瘤的病例,该病例说明了在尿CYT标本中直接双重免疫染色检测细胞角蛋白20(CK20)/p53表达的诊断效用。一名42岁女性因右下腹部疼痛就诊于急诊室。计算机断层扫描显示肾后梗阻性肾积水,其尿CYT显示为恶性肿瘤,类型未确定。CK20胞质表达和p53核表达呈阳性的非典型细胞有助于决定是否对尿路上皮癌进行肾输尿管切除术。

相似文献

1
Diagnostic utility of double immunostaining of a urine cytology preparation for cytokeratin 20/p53 expression in a young woman with micropapillary urothelial carcinoma of the renal pelvis presenting as an unknown primary malignancy.一名年轻女性肾盂微乳头尿路上皮癌表现为原发灶不明的恶性肿瘤,尿细胞学涂片细胞角蛋白20/p53表达双重免疫染色的诊断效用
Cytojournal. 2016 Nov 16;13:26. doi: 10.4103/1742-6413.194162. eCollection 2016.
2
Diagnostic significance of dual immunocytochemical staining of p53/cytokeratin20 on liquid-based urine cytology to detect urothelial carcinoma.p53/细胞角蛋白20双重免疫细胞化学染色在液基尿细胞学检查中对检测尿路上皮癌的诊断意义
Cytojournal. 2020 Feb 27;17:3. doi: 10.25259/Cytojournal_88_2019. eCollection 2020.
3
Diagnostic Significance of Cytokeratin 20 and p53 as Adjunct Immunocytological Markers in Urine Cytology to Detect Urothelial Carcinomas: A Systematic Review Study.细胞角蛋白20和p53作为尿液细胞学辅助免疫细胞标志物在检测尿路上皮癌中的诊断意义:一项系统评价研究
Iran J Pathol. 2023 Summer;18(3):257-269. doi: 10.30699/IJP.2023.1972203.3004. Epub 2023 Jul 16.
4
Evaluation of a triple combination of cytokeratin 20, p53 and CD44 for improving detection of urothelial carcinoma in urine cytology specimens.评估细胞角蛋白20、p53和CD44三联组合用于提高尿液细胞学标本中尿路上皮癌检测率的研究。
Cytojournal. 2013 Dec 27;10:25. doi: 10.4103/1742-6413.123784. eCollection 2013.
5
Cytokeratin 20 immunocytochemistry on urine sediments: A potential low-cost adjunct to cytology in the diagnosis of low-grade urothelial carcinoma.尿沉渣细胞角蛋白20免疫细胞化学:一种用于诊断低级别尿路上皮癌的潜在低成本细胞学辅助方法。
Cytopathology. 2017 Dec;28(6):531-535. doi: 10.1111/cyt.12463. Epub 2017 Sep 22.
6
Cytokeratin 20/p53 dual immunocytochemistry for improving the diagnostic accuracy of urine liquid-based cytology in the detection of urothelial neoplasm: A retrospective study.细胞角蛋白20/p53双重免疫细胞化学用于提高尿液液基细胞学检测尿路上皮肿瘤的诊断准确性:一项回顾性研究。
Cytojournal. 2017 Nov 24;14:27. doi: 10.4103/cytojournal.cytojournal_23_17. eCollection 2017.
7
Expression of cytokeratin 20 in urine cytology smears: a potential marker for the detection of urothelial carcinoma.细胞角蛋白20在尿液细胞学涂片中的表达:一种检测尿路上皮癌的潜在标志物。
Cytopathology. 2007 Apr;18(2):84-6. doi: 10.1111/j.1365-2303.2006.00432.x.
8
Urothelial carcinoma with oncocytic features: an extremely rare case presenting a diagnostic challenge in urine cytology.具有嗜酸性细胞特征的尿路上皮癌:一例极其罕见的病例,在尿液细胞学检查中带来诊断挑战。
Int J Clin Exp Pathol. 2015 Jul 1;8(7):8591-7. eCollection 2015.
9
Cytokeratin-20 immunocytochemistry in voided urine cytology and its comparison with nuclear matrix protein-22 and urine cytology in the detection of urothelial carcinoma.尿脱落细胞学中细胞角蛋白-20免疫细胞化学及其在检测尿路上皮癌中与核基质蛋白-22和尿细胞学的比较。
Diagn Cytopathol. 2012 Sep;40(9):755-9. doi: 10.1002/dc.21617. Epub 2011 Jan 6.
10
Cytokeratin 20 as an immunocytochemical marker for detection of urothelial carcinoma in atypical cytology: preliminary retrospective study on archived urine slides.细胞角蛋白20作为免疫细胞化学标志物用于非典型细胞学中尿路上皮癌的检测:对存档尿涂片的初步回顾性研究
Cancer Detect Prev. 2001;25(2):202-9.

引用本文的文献

1
Cytokeratin 20/p53 dual immunocytochemistry for improving the diagnostic accuracy of urine liquid-based cytology in the detection of urothelial neoplasm: A retrospective study.细胞角蛋白20/p53双重免疫细胞化学用于提高尿液液基细胞学检测尿路上皮肿瘤的诊断准确性:一项回顾性研究。
Cytojournal. 2017 Nov 24;14:27. doi: 10.4103/cytojournal.cytojournal_23_17. eCollection 2017.

本文引用的文献

1
The utility of p63, p40, and GATA-binding protein 3 immunohistochemistry in diagnosing micropapillary urothelial carcinoma.p63、p40和GATA结合蛋白3免疫组化在诊断微乳头型尿路上皮癌中的应用
Hum Pathol. 2014 Sep;45(9):1824-9. doi: 10.1016/j.humpath.2014.04.015. Epub 2014 May 8.
2
Evaluation of a triple combination of cytokeratin 20, p53 and CD44 for improving detection of urothelial carcinoma in urine cytology specimens.评估细胞角蛋白20、p53和CD44三联组合用于提高尿液细胞学标本中尿路上皮癌检测率的研究。
Cytojournal. 2013 Dec 27;10:25. doi: 10.4103/1742-6413.123784. eCollection 2013.
3
Cytological findings of the micropapillary variant of urothelial carcinoma: a comparison with typical high-grade urothelial carcinoma.
尿路上皮癌微乳头变体的细胞学发现:与典型高级别尿路上皮癌的比较。
Korean J Pathol. 2013 Aug;47(4):365-71. doi: 10.4132/KoreanJPathol.2013.47.4.365. Epub 2013 Aug 26.
4
Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma.联合细胞学和分子尿液标志物应用以提高尿路上皮癌的检测率。
Cancer Cytopathol. 2013 May;121(5):252-60. doi: 10.1002/cncy.21247. Epub 2012 Nov 21.
5
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.EAU 指南:非肌层浸润性膀胱尿路上皮癌,2011 年更新版。
Eur Urol. 2011 Jun;59(6):997-1008. doi: 10.1016/j.eururo.2011.03.017. Epub 2011 Mar 22.
6
Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system.国家癌症报告:1975-2007 年癌症发病与死亡统计,重点介绍脑和神经系统肿瘤。
J Natl Cancer Inst. 2011 May 4;103(9):714-36. doi: 10.1093/jnci/djr077. Epub 2011 Mar 31.
7
Multiprobe fluorescence in situ hybridization (UroVysion) for the detection of urothelial carcinoma - FISHing for the right catch.用于检测尿路上皮癌的多探针荧光原位杂交技术(UroVysion)——精准捕捉的荧光原位杂交技术
Acta Cytol. 2011;55(2):113-9. doi: 10.1159/000323652. Epub 2011 Feb 15.
8
Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer.膀胱癌的检测和随访中,光动力诊断和尿液生物标志物(荧光原位杂交技术、免疫细胞化学、核基质蛋白 22)及细胞学的临床有效性和成本效益的系统评价。
Health Technol Assess. 2010 Jan;14(4):1-331, iii-iv. doi: 10.3310/hta14040.
9
Biomarkers for detection and surveillance of bladder cancer.用于膀胱癌检测和监测的生物标志物。
Can Urol Assoc J. 2008 Jun;2(3):212-21. doi: 10.5489/cuaj.600.
10
Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.原位尿路上皮癌与非肿瘤性尿路上皮的鉴别性免疫组化染色:细胞角蛋白20、p53和CD44抗原分析
Am J Surg Pathol. 2001 Aug;25(8):1074-8. doi: 10.1097/00000478-200108000-00013.